?-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

家学曹
2021-06-29

?

JPMorgan: These three U.S. stocks are expected to rise by more than 70%

智通财经APP获悉，近日，来自摩根大通的专业人士认为，以下三只股票拥有潜在的投资机会，其潜在的收益可能高达70%或以上。 Day One Biopharmaceuticals(DAWN.US) Day

JPMorgan: These three U.S. stocks are expected to rise by more than 70%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":159890075,"tweetId":"159890075","gmtCreate":1624954048897,"gmtModify":1703848720262,"author":{"id":3585982655057521,"idStr":"3585982655057521","authorId":3585982655057521,"authorIdStr":"3585982655057521","name":"家学曹","avatar":"https://static.tigerbbs.com/0788bf0a88e8edc25921e1d7c24b6c0b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>?</p></body></html>","htmlText":"<html><head></head><body><p>?</p></body></html>","text":"?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/159890075","repostId":2147703851,"repostType":4,"repost":{"id":"2147703851","kind":"highlight","pubTimestamp":1624952012,"share":"https://ttm.financial/m/news/2147703851?lang=en_US&edition=fundamental","pubTime":"2021-06-29 15:33","market":"us","language":"zh","title":"JPMorgan: These three U.S. stocks are expected to rise by more than 70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2147703851","media":"智通财经网","summary":"智通财经APP获悉，近日，来自摩根大通的专业人士认为，以下三只股票拥有潜在的投资机会，其潜在的收益可能高达70%或以上。\nDay One Biopharmaceuticals(DAWN.US)\nDay","content":"<p>Zhitong Finance APP learned that recently, from<a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Professionals believe that the following three stocks have potential investment opportunities, and their potential returns may be as high as 70% or more.</p><p><b>Day One Biopharmaceuticals (DAWN.US)</b></p><p>Day One is a biotech company. Its current lead drug candidate development is DAY101, an oral, selective type II pan-RAF kinase inhibitor, which is being evaluated in a pivotal phase 2 clinical trial. The trial has enrolled pediatric, adolescent, and young adult patients. All patients in the study had recurrent or progressive low-grade glioma (pLGG).</p><p>DAY101 has received two important designations from the FDA, namely breakthrough drug designation and rare drug designation, and the company plans to conduct more clinical trials.</p><p>The company launched an initial public offering in late May, offering 10 million shares to the market at $16 per share. The event raised $160 million in funding. Day One has been included in the Nasdaq index and has a market capitalization of $1.24 billion.</p><p>JPMorgan analyst Anupam Rama likes the fundamentals of this newly listed bio company. The analyst has given Day One a \"buy\" investment rating and a $38 price target.</p><p>\"The reason for our increase is the company's research and development drug DAY101, which was originally developed as a leading drug to treat recurrent low-grade glioma in children caused by the BRAF gene. At present, it seems that the known data shows early anti-tumor activity and safety, and reduces the risk of glioma recurrence in patients in phase 2 clinical trials.\" Rama said.</p><p>If the analyst's thesis materializes in the coming months, the stock could appreciate by 89%.</p><p><b>Altice USA (ATUS.US)</b></p><p>Altice is an American cable television provider. Altice's business has been solid for a long time, with the company's stock up 52% over the past 12 months. The company consistently ranks among the top 5 cable companies in the US market by customer base.</p><p>Altice's first-quarter earnings report showed strong cash flow. Operating cash flow increased more than 17% year-over-year to $862 million. The growth was partly driven by earnings growth and partly by lower capital expenditures.</p><p>Philip Cusick, an analyst at JPMorgan Chase, was impressed by Altice's solid business foundation. He pointed out: \"We will continue to be bullish on ATUS because of its solid fundamentals, strong capital returns, and attractive valuation (based on the 2021 after-tax cash flow yield of 10.3%) and single-digit revenue growth rate, etc. Altice is still on track to achieve its 2021 residential broadband subscriber growth target, basically maintaining its growth rates in 2019 and 2018 or even better.\"</p><p>Therefore, Cusick gave Altice an \"overweight\" investment rating and a target price of $62. This price implies an 80% upside over the next 12 months.</p><p><b>Similarweb (SMWB.US)</b></p><p>Similarweb is a digital<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>And web analytics company, founded in 2007 for the small and medium-sized business market. Similarweb's revenue last year reached $93.5 million. The company went public in May this year. It issued 7.5 million shares on the market at a price of $22 per share, raising a total of about $165 million.</p><p>The newly listed stock caught the attention of JPMorgan analyst Sterling Auty, who sees a market close to $34 billion for Similarweb's services.</p><p>\"More and more enterprises are transforming into digital marketization routes, including e-commerce, forcing investors to look for reliable alternative data sources to operate and invest in businesses. Similarweb has established itself as a leading digital intelligence platform for Internet, mobile Internet and mobile application data. We believe this position will lead to sustained and rapid revenue growth and increasing operating leverage, ultimately driving excess returns for stocks,\" Auty believes.</p><p>Auty has assigned Similarweb an investment rating of \"buy\" and a $31 price target. This price target implies a potential 70% upside for the stock over the next 12 months.</p>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan: These three U.S. stocks are expected to rise by more than 70%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan: These three U.S. stocks are expected to rise by more than 70%\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经网</strong><span class=\"h-time small\">2021-06-29 15:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Zhitong Finance APP learned that recently, from<a href=\"https://laohu8.com/S/JPM\">JPMorgan Chase</a>Professionals believe that the following three stocks have potential investment opportunities, and their potential returns may be as high as 70% or more.</p><p><b>Day One Biopharmaceuticals (DAWN.US)</b></p><p>Day One is a biotech company. Its current lead drug candidate development is DAY101, an oral, selective type II pan-RAF kinase inhibitor, which is being evaluated in a pivotal phase 2 clinical trial. The trial has enrolled pediatric, adolescent, and young adult patients. All patients in the study had recurrent or progressive low-grade glioma (pLGG).</p><p>DAY101 has received two important designations from the FDA, namely breakthrough drug designation and rare drug designation, and the company plans to conduct more clinical trials.</p><p>The company launched an initial public offering in late May, offering 10 million shares to the market at $16 per share. The event raised $160 million in funding. Day One has been included in the Nasdaq index and has a market capitalization of $1.24 billion.</p><p>JPMorgan analyst Anupam Rama likes the fundamentals of this newly listed bio company. The analyst has given Day One a \"buy\" investment rating and a $38 price target.</p><p>\"The reason for our increase is the company's research and development drug DAY101, which was originally developed as a leading drug to treat recurrent low-grade glioma in children caused by the BRAF gene. At present, it seems that the known data shows early anti-tumor activity and safety, and reduces the risk of glioma recurrence in patients in phase 2 clinical trials.\" Rama said.</p><p>If the analyst's thesis materializes in the coming months, the stock could appreciate by 89%.</p><p><b>Altice USA (ATUS.US)</b></p><p>Altice is an American cable television provider. Altice's business has been solid for a long time, with the company's stock up 52% over the past 12 months. The company consistently ranks among the top 5 cable companies in the US market by customer base.</p><p>Altice's first-quarter earnings report showed strong cash flow. Operating cash flow increased more than 17% year-over-year to $862 million. The growth was partly driven by earnings growth and partly by lower capital expenditures.</p><p>Philip Cusick, an analyst at JPMorgan Chase, was impressed by Altice's solid business foundation. He pointed out: \"We will continue to be bullish on ATUS because of its solid fundamentals, strong capital returns, and attractive valuation (based on the 2021 after-tax cash flow yield of 10.3%) and single-digit revenue growth rate, etc. Altice is still on track to achieve its 2021 residential broadband subscriber growth target, basically maintaining its growth rates in 2019 and 2018 or even better.\"</p><p>Therefore, Cusick gave Altice an \"overweight\" investment rating and a target price of $62. This price implies an 80% upside over the next 12 months.</p><p><b>Similarweb (SMWB.US)</b></p><p>Similarweb is a digital<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>And web analytics company, founded in 2007 for the small and medium-sized business market. Similarweb's revenue last year reached $93.5 million. The company went public in May this year. It issued 7.5 million shares on the market at a price of $22 per share, raising a total of about $165 million.</p><p>The newly listed stock caught the attention of JPMorgan analyst Sterling Auty, who sees a market close to $34 billion for Similarweb's services.</p><p>\"More and more enterprises are transforming into digital marketization routes, including e-commerce, forcing investors to look for reliable alternative data sources to operate and invest in businesses. Similarweb has established itself as a leading digital intelligence platform for Internet, mobile Internet and mobile application data. We believe this position will lead to sustained and rapid revenue growth and increasing operating leverage, ultimately driving excess returns for stocks,\" Auty believes.</p><p>Auty has assigned Similarweb an investment rating of \"buy\" and a $31 price target. This price target implies a potential 70% upside for the stock over the next 12 months.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/503260.html\">智通财经网</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/a19b23dfbd7f00895c2f7282a2eac809","relate_stocks":{"JPM":"摩根大通"},"source_url":"http://www.zhitongcaijing.com/content/detail/503260.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2147703851","content_text":"智通财经APP获悉，近日，来自摩根大通的专业人士认为，以下三只股票拥有潜在的投资机会，其潜在的收益可能高达70%或以上。\nDay One Biopharmaceuticals(DAWN.US)\nDay One是一家生物科技公司。其目前主要候选药物研发是DAY101，一种口服的、选择性的II型pan-RAF激酶抑制剂，正在进行一项关键的2期临床试验的评估。该试验已经招募了儿童、青少年和年轻成人患者。研究中的所有患者都患有复发性或进展性低级别胶质瘤（pLGG）。\nDAY101已获得FDA的两项重要认定，即突破性药物认定和罕用药物认定，而且该公司还计划进行更多的临床试验。\n该公司在5月底进行了首次公开募股，以每股16美元的价格向市场发放了1000万股。这次活动筹集了1.6亿美元的资金。Day One已被纳入纳斯达克指数，市值为12.4亿美元。\n摩根大通的分析师Anupam Rama喜欢这只新上市生物公司的基本面。该分析师给予Day One“买入”的投资评级，并给出了38美元的目标价。\n\"我们的增持原因是公司的研发药物DAY101，它作为领先的药物最初被开发来用于治疗BRAF基因导致的儿童复发性低级别胶质瘤。目前看来，已知的数据显示了早期抗肿瘤活性和安全性，在2期临床实验中降低了患者胶质瘤复发的风险。\" Rama说道。\n如果分析师的论点在未来几个月得以实现，股票可能升值89%。\nAltice USA(ATUS.US)\nAltice是一家美国有线电视供应商。长期以来，Altice的业务一直很稳定，在过去的12个月里，该公司的股票上涨了52%。按客户基数计算，该公司一直在美国市场上排名前5位的有线电视公司。\nAltice第一季度财报展示了强劲的现金流。经营性现金流同比增长超过17%，达到8.62亿美元。增长部分原因是由盈利增长推动的，另一部分是由资本支出减少。\n摩根大通的分析师Philip Cusick对Altice稳固的业务基础印象深刻，他指出：“我们将继续看好ATUS，因为它有着稳固的基本面，强劲的资本回报，以及具有吸引力的估值（基于2021年税后现金流的收益率10.3%计算）和个位数的收入增长率等等。Altice仍然有望实现其2021年居民宽带用户增长的目标，基本能保持其在2019年和2018年时的增长率甚至更好。\"\n因此，Cusick给予Altice“增持”的投资评级，和62美元的目标价。这个价格意味着未来12个月有80%的上升空间。\nSimilarweb(SMWB.US)　　\nSimilarweb是一家数字智能和网络分析公司，成立于2007年，面向中小型企业市场。Similarweb去年的收入达到9350万美元，该公司在今年5月上市，其在市场上发行了750万股股票，每股价格为22美元，总共筹集了约1.65亿美元的资金。\n这支新上市的股票引起了摩根大通分析师Sterling Auty的注意，他认为Similarweb的服务有接近340亿美元的市场。\n\"越来越多的企业转型为包括电子商务在内的数字市场化路线，迫使广大投资者寻找可靠的替代数据源来经营和投资企业。Similarweb已经确立了自己在互联网、移动互联网和移动应用数据方面的领先数字智能平台地位。我们相信，这种地位将带来持续快速的收入增长和经营杠杆的不断增加，最终推动股票的超额收益。\"Auty认为。\nAuty给予Similarweb“买入”的投资评级，31美元的目标价。该目标价意味着该股票在未来12个月内可能有70%的上升空间。","news_type":1,"symbols_score_info":{"JPM":0.9}},"isVote":1,"tweetType":1,"viewCount":1463,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}